Aquestive Therapeutics, a drug manufacturer developing oral film formulations of CNS disease therapies, raised $68 million by offering 4.5 million shares at $15, within the range of $14 to $16. Insiders intended to purchase $20 million of the IPO (30% of the deal). Aquestive Therapeutics plans to list on the Nasdaq under the symbol AQST. BMO Capital Markets and RBC Capital Markets acted as lead managers on the deal.
